Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2022)
13 slides from Biotron's shareholder meeting presentation, Nov 16, 2022
Slide 1: Cover letter to ASX: Presentation to Annual General Meeting
Level 2, 66 Hunter Street Sydney NSW 2000 For personal use only Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 16 November 2022 The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000 (13 pages by email) Dear Madam, PRESENTATION
Slide 2: Chairman's Address to the AGM
Level 2, 66 Hunter Street Sydney NSW 2000 For personal use only Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 16 November 2022 CHAIRMAN’S ADDRESS TO THE AGM My Fellow Shareholders After an enforced three year absence it is a pleasure to r
Slide 3: Chairman's Address (continued)
Biotron is a small Australian biotechnology company with international ambitions. The markets we expect to enter are huge. This drives our conservative, step-wise strategy. The science at the core of the Company’s endeavours is unquestionably sound. Our results to date speak for themselves. Nine For
Slide 4: Biotron Limited Annual General Meeting 16 November 2022
For personal use only BIOTRON LIMITED (ASX:BIT) Annual General Meeting 16 November 2022
Slide 5: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These state
Slide 6: Key Achievements in 2021/2022 FY
Key Achievements in 2021/2022 FY For personal use only • Completed enrolment of two Phase 2 HIV-1 clinical trials that build on positive results in previous clinical studies • Results expected mid-2023 • These studies are key to positioning of BIT225 for partnering • Demonstrated that BIT225 stops r
Slide 7: HIV-1 Clinical Program Update
HIV-1 Clinical Program Update For personal use only • Two Phase 2 HIV-1 clinical trials currently in progress at sites in Sydney, Australia (Holdsworth House, East Sydney Doctors and St Vincent’s Hospital, Darlinghurst) and in Thailand (Bangkok and Chiang Mai) • Both trials are fully recruited • Res
Slide 8: HIV-1 Market Opportunity
HIV-1 Market Opportunity • In 2021, despite availability of antiretroviral drugs (ART) - For personal use only • Over 38.4 million people globally were living with HIV • 1.5 million newly infected with the virus • An estimated 650,000 people died from AIDS-related illnesses. • The global HIV drug ma
Slide 9: SARS-CoV-2/COVID-19 Program Update
SARS-CoV-2/COVID-19 Program Update For personal use only • BIT225 has demonstrated ability to prevent COVID-19, reduce virus and stop the cytokine storm in a relevant, robust, industry-recognised animal model of disease* • A human COVID-19 study is in progress as a sub-study in Thailand in one of th
Slide 10: Ongoing Need for SARS-CoV-2/COVID-19 Anti-Viral Drugs
Ongoing Need for SARS-CoV-2/COVID-19 Anti-Viral Drugs For personal use only • Vaccines remain central to control of the pandemic but there is an unmet need for effective drugs to treat COVID • Uncertain global pandemic outlook • On-going risk of emergence of new SARS-CoV-2 variants • At risk populat
Slide 11: BIT225 Opportunity Summary
BIT225 Opportunity Summary For personal use only • BIT225 is a very important clinical asset for Biotron • Previous positive clinical trial data have significantly de-risked the program • Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be used to
Slide 12: Outlook for 2023
Outlook for 2023 • 2023 will be an important year for this Company For personal use only • Results of three Phase 2 clinical trials expected in mid-2023 • Two Phase 2 HIV-1 clinical trials • Includes the COVID-19 sub-study that is in progress • New Phase 2 COVID clinical trial (subject to funding) •
Slide 13: Biotron Limited
BIOTRON LIMITED For personal use only (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329